Developer docs
API playgroundTry for free, no card

Search company profiles

Lunatus

Full company profile

uuid002nd74

Namestring
Lunatus
Legal namestring
Lunatus Marketing & Consulting FZCO
Websiteurl
lunatus-me.com
Company typeenum
Private
Founded yearint
2003
Descriptiontext

Lunatus Marketing & Consulting FZCO is a Dubai-headquartered, private healthcare commercialization partner founded in 2003 by Lina Kouatly (President & CEO). The company acts as the regional conduit between international pharmaceutical and healthcare manufacturers and the markets of the Arabian Gulf and Middle East, operating across nine countries: UAE, Saudi Arabia, Kuwait, Qatar, Bahrain, Oman, Jordan, Lebanon, and Iraq. It commercializes 300+ product lines sourced from 40+ global healthcare partners across 16 therapeutic categories including cardiovascular, dermatology, ENT, gastroenterology, gynecology, infectious diseases, internal medicine, neurology, oncology, ophthalmology, orthopaedic, pain management, pediatrics, psychiatric, vascular, and weight loss.

The company's offering is structured as a full-stack commercialization service — covering in-house regulatory affairs supported by in-house legal counsel, sales force deployment, marketing execution, distribution logistics, and supply chain management — that replaces the need for international pharma companies to engage multiple local vendors when entering the region. Underlying technology is not specified, and there is no disclosed proprietary software platform or AI component; the value lies in process integration, regulatory know-how, and regional infrastructure rather than technology IP. The company is privately held with no disclosed parent, funding rounds, or institutional shareholders.

Revenue is generated through exclusive distribution and commercialization agreements: Lunatus retains exclusive commercialization rights for partnered products in defined Middle Eastern territories and shares economics with the originator via upfront payments, regulatory and commercial milestone payments, and a significant share of in-region product revenue. Recent marquee agreements include an exclusive partnership with LENZ Therapeutics for VIZZ (aceclidine ophthalmic solution) for presbyopia, signed in January 2026. Pricing is not publicly disclosed, revenue figures are not publicly disclosed, and the firm employs between 51 and 100 people across its regional operations.

Short descriptiontext

Lunatus is a Dubai-based, private healthcare commercialization partner founded in 2003 that gives international pharmaceutical companies exclusive regulatory, sales, marketing, distribution, and supply chain access across nine Middle Eastern countries, commercializing 300+ products from 40+ global partners.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersDubai, United Arab Emirates
HQ citystring
Dubai
HQ countrystring
United Arab Emirates
HQ regionstring
Middle East
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
pharmaceutical distribution, healthcare commercialization, regulatory affairs services, pharmaceutical marketing, medical supply chain
Industry2 codes
PRIMARYHLAIAJAO
Compounding Ingredient & API Distributors (Pharma Supply)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Distribution & Wholesaling
SECONDARYMPAAAFAL
International / Market Entry & Expansion Marketing Strategy
NAICS code3 codes
  • Drugs and Druggists' Sundries Merchant Wholesalers424210
  • Drugs and Druggists' Sundries Merchant Wholesalers42421
  • Wholesale Trade Agents and Brokers425120
SIC code1 code
  • Wholesale-Drugs, Proprietaries & Druggists' Sundries5122
Product category
Pharmaceutical Distribution and Commercialization Services
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Distribution and Commercialization Rights
TypeTransaction Fee
Description

Lunatus generates revenue through exclusive distribution agreements with global healthcare companies. They receive upfront payments, regulatory milestones, commercial milestones, and a significant share of product revenue from sales in the Middle East region.

ir.lenz-tx.com
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Personnel, Operations, Marketing or Sales, Supply Chain
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Lunatus acts as a full-service healthcare commercialization partner for global pharmaceutical and healthcare companies seeking to enter Middle East markets. The company delivers integrated regulatory, sales, marketing, distribution, and supply chain solutions, and commercializes a portfolio of 300+ product lines across 16 therapeutic categories sourced from 40+ international partners. Its core revenue model combines exclusive distribution rights with milestone payments and revenue shares from partnered product launches in the Arabian Gulf region.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Lunatus operates as a full-service healthcare commercialization partner rather than a product manufacturer. The company offers regulatory, sales, marketing, distribution, and supply chain solutions to help global pharmaceutical companies enter and expand in Middle East markets. Their portfolio spans 16 therapeutic categories (Cardiovascular, Dermatology, ENT, Gastroenterology, Gynecology, Infectious Diseases, Internal Medicine, Neurology, Oncology, Ophthalmology, Orthopaedic, Pain Management, Pediatrics, Psychiatric, Vascular, and Weight Loss) across 300+ product lines from 40+ international partners. A notable product within their Ophthalmology category is VIZZ (aceclidine ophthalmic solution), which they commercialize in the Middle East in partnership with LENZ Therapeutics.

Product and service7 records
1Healthcare Product Portfolio (300+ product lines across 16 therapeutic categories)
CategoryPharmaceutical Distribution / Healthcare Products
Description

Diverse portfolio of over 300 healthcare product lines across 16 therapeutic categories (Cardiovascular, Dermatology, ENT, Gastroenterology, Gynecology, Infectious Diseases, Internal Medicine, Neurology, Oncology, Ophthalmology, Orthopaedic, Pain Management, Pediatrics, Psychiatric, Vascular, and Weight Loss), sourced from more than 40 global pharmaceutical partners and commercialized for global healthcare companies seeking to reach Middle East markets.

2VIZZ (aceclidine ophthalmic solution)
CategoryOphthalmology Pharmaceutical Product
Description

Aceclidine ophthalmic solution for the treatment of presbyopia, commercialized in the Middle East under an exclusive partnership with LENZ Therapeutics. Lunatus holds exclusive commercialization rights across nine Middle Eastern countries.

3Regulatory Affairs Services
CategoryRegulatory Services
Description

Regulatory support delivered through an in-house regulatory team that works hand-in-hand with the company's legal counsel to navigate complex Middle East approval requirements for partnered pharmaceutical and healthcare products.

4Sales Services
CategorySales Services
Description

Sales force deployment and execution for partnered pharmaceutical and healthcare products across the Arabian Gulf and Middle East region.

5Marketing Services
CategoryMarketing Services
Description

Comprehensive marketing strategy crafting and execution for partnered healthcare brands across the Middle East region.

6Distribution Services
CategoryDistribution Services
Description

Distribution strategy and execution that delivers partnered pharmaceutical and healthcare products across nine Middle Eastern countries (UAE, Saudi Arabia, Kuwait, Qatar, Bahrain, Oman, Jordan, Lebanon, and Iraq).

7Supply Chain Management Services
CategorySupply Chain Management Services
Description

Reliability-focused supply chain management woven into every stage of the product lifecycle, ensuring product security for partnered pharmaceutical and healthcare brands across the Middle East.

Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2026-01-05
Description

Exclusive commercialization partnership for VIZZ (aceclidine ophthalmic solution) for treating presbyopia in the Middle East region, covering UAE, Saudi Arabia, Kuwait, Qatar, Bahrain, Oman, Jordan, Lebanon, and Iraq. LENZ receives upfront, regulatory and commercial milestone payments plus a significant share of revenue, while Lunatus retains exclusive commercialization rights. This is LENZ's fourth international commercialization partnership for VIZZ, which received FDA approval in July 2025 and launched in the US in September 2025.

240+ Global Healthcare Companies
Strategic tierCoreTypeChannel Partner/ Reseller/ Distributor
Description

Partnered with over 40 global companies offering 300 diverse product lines to meet the growing healthcare needs of the Middle East region across cardiovascular, dermatology, ENT, gastroenterology, gynecology, infectious diseases, internal medicine, neurology, oncology, ophthalmology, orthopaedic, pain management, pediatrics, psychiatric, vascular, and weight loss categories.

lunatus.com
Recent move4 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Lebanon-based pharmaceutical company with manufacturing and regional distribution across MENA, including in-licensed and proprietary branded generics. Comparable regional pharmaceutical distributor serving overlapping Middle Eastern markets.

TypeDirect peer
Description

Saudi-based pharmaceutical company with manufacturing, in-licensing, and regional distribution across multiple therapeutic categories. Directly comparable to Lunatus's business model of partnering with global innovators for Middle East commercialization.

TypeBroad incumbent
Description

India-headquartered global pharmaceutical major with active presence in the Middle East via distribution partnerships and direct operations. Comparable as both a potential partner to Lunatus and a broader incumbent operating in the same regional channel.

TypeBroad incumbent
Description

Jordan-headquartered multinational pharmaceutical company with deep MENA commercial infrastructure, branded and generics portfolio, and a licensing/distribution model overlapping Lunatus's go-to-market. Larger and more diversified, but operates in the same channel.

TypeDirect peer
Description

Abu Dhabi-headquartered pharmaceutical manufacturer with regional distribution across the GCC. Operates a similar in-licensing and distribution model serving MENA markets and overlapping with Lunatus's therapeutic categories.

6Julphar (Gulf Pharmaceutical Industries)
TypeDirect peer
Description

Ras Al Khaimah-based pharmaceutical manufacturer and distributor with broad MENA presence across multiple therapeutic categories. Direct comparable: UAE-headquartered pharma player offering branded generics and licensing partnerships across the same Gulf geographies Lunatus serves.

7Pharmax Pharmaceuticals
TypeDirect peer
Description

UAE-based pharmaceutical company specializing in branded generics and in-licensed products with regional distribution across the Middle East. Closely comparable business model — in-licensing, marketing, and distribution via regional channel partners.

TypeRegional player
Description

Switzerland-headquartered but with a strong Middle East/Turkey focus for specialty pharmaceuticals via partnerships and out-licensing. Comparable as a partner-to-Lunatus originator (or regional distributor) rather than a direct competitor in the Gulf.

TypeDirect peer
Description

Saudi-listed pharmaceutical manufacturer and distributor serving KSA and export markets with branded and licensed products. Comparable regional distribution footprint and licensing/partnership-driven model targeting the same Middle Eastern customer base as Lunatus.

10Jamjoom Pharmaceuticals
TypeDirect peer
Description

Saudi-based pharmaceutical company with manufacturing, marketing, and distribution of branded generics and licensed products across MENA. Comparable in-licensing/distribution orientation and GCC market focus.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Lunatus

Pharmaceutical Distribution and Commercialization Serviceslunatus-me.com

Lunatus is a Dubai-based, private healthcare commercialization partner founded in 2003 that gives international pharmaceutical companies exclusive regulatory, sales, marketing, distribution, and supply chain access across nine Middle Eastern countries, commercializing 300+ products from 40+ global partners.

What Lunatus does

Lunatus Marketing & Consulting FZCO is a Dubai-headquartered, private healthcare commercialization partner founded in 2003 by Lina Kouatly (President & CEO). The company acts as the regional conduit between international pharmaceutical and healthcare manufacturers and the markets of the Arabian Gulf and Middle East, operating across nine countries: UAE, Saudi Arabia, Kuwait, Qatar, Bahrain, Oman, Jordan, Lebanon, and Iraq. It commercializes 300+ product lines sourced from 40+ global healthcare partners across 16 therapeutic categories including cardiovascular, dermatology, ENT, gastroenterology, gynecology, infectious diseases, internal medicine, neurology, oncology, ophthalmology, orthopaedic, pain management, pediatrics, psychiatric, vascular, and weight loss.

The company's offering is structured as a full-stack commercialization service — covering in-house regulatory affairs supported by in-house legal counsel, sales force deployment, marketing execution, distribution logistics, and supply chain management — that replaces the need for international pharma companies to engage multiple local vendors when entering the region. Underlying technology is not specified, and there is no disclosed proprietary software platform or AI component; the value lies in process integration, regulatory know-how, and regional infrastructure rather than technology IP. The company is privately held with no disclosed parent, funding rounds, or institutional shareholders.

Revenue is generated through exclusive distribution and commercialization agreements: Lunatus retains exclusive commercialization rights for partnered products in defined Middle Eastern territories and shares economics with the originator via upfront payments, regulatory and commercial milestone payments, and a significant share of in-region product revenue. Recent marquee agreements include an exclusive partnership with LENZ Therapeutics for VIZZ (aceclidine ophthalmic solution) for presbyopia, signed in January 2026. Pricing is not publicly disclosed, revenue figures are not publicly disclosed, and the firm employs between 51 and 100 people across its regional operations.

Lunatus firmographics

Firmographics
Name
Lunatus
Legal name
Lunatus Marketing & Consulting FZCO
Website
https://lunatus-me.com
Company type
Private
Founded year
2003
Operating status
Operating
Headcount range
101–250 employees
Short description
Lunatus is a Dubai-based, private healthcare commercialization partner founded in 2003 that gives international pharmaceutical companies exclusive regulatory, sales, marketing, distribution, and supply chain access across nine Middle Eastern countries, commercializing 300+ products from 40+ global partners.
Ownership category
akta.pro rank

Lunatus industry classification

Industry
Product category
Pharmaceutical Distribution and Commercialization Services
NAICS
Drugs and Druggists' Sundries Merchant Wholesalers (424210), Drugs and Druggists' Sundries Merchant Wholesalers (42421), Wholesale Trade Agents and Brokers (425120)
SIC
Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)
akta.pro industry
PRIMARYHLAIAJAO
Compounding Ingredient & API Distributors (Pharma Supply)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Distribution & Wholesaling
SECONDARYMPAAAFAL
International / Market Entry & Expansion Marketing Strategy

Keywords

  • Pharmaceutical distribution
  • Healthcare commercialization
  • Regulatory affairs services
  • Pharmaceutical marketing
  • Medical supply chain

Where Lunatus is headquartered

Location

Headquarters

HQ city
Dubai
HQ country
United Arab Emirates
HQ region
Middle East

Offices1 record

Markets served

Lunatus business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Marketing or Sales, Supply Chain

Revenue model

  1. Distribution and Commercialization Rights: Lunatus generates revenue through exclusive distribution agreements with global healthcare companies. They receive upfront payments, regulatory milestones, commercial milestones, and a significant share of product revenue from sales in the Middle East region.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Lunatus product offering

Product offering

Core offering

Lunatus acts as a full-service healthcare commercialization partner for global pharmaceutical and healthcare companies seeking to enter Middle East markets. The company delivers integrated regulatory, sales, marketing, distribution, and supply chain solutions, and commercializes a portfolio of 300+ product lines across 16 therapeutic categories sourced from 40+ international partners. Its core revenue model combines exclusive distribution rights with milestone payments and revenue shares from partnered product launches in the Arabian Gulf region.

Product overview

Lunatus operates as a full-service healthcare commercialization partner rather than a product manufacturer. The company offers regulatory, sales, marketing, distribution, and supply chain solutions to help global pharmaceutical companies enter and expand in Middle East markets. Their portfolio spans 16 therapeutic categories (Cardiovascular, Dermatology, ENT, Gastroenterology, Gynecology, Infectious Diseases, Internal Medicine, Neurology, Oncology, Ophthalmology, Orthopaedic, Pain Management, Pediatrics, Psychiatric, Vascular, and Weight Loss) across 300+ product lines from 40+ international partners. A notable product within their Ophthalmology category is VIZZ (aceclidine ophthalmic solution), which they commercialize in the Middle East in partnership with LENZ Therapeutics.

Differentiator

Problem solved

Functional benefit

Products and services

  • Healthcare Product Portfolio (300+ product lines across 16 therapeutic categories) Diverse portfolio of over 300 healthcare product lines across 16 therapeutic categories (Cardiovascular, Dermatology, ENT, Gastroenterology, Gynecology, Infectious Diseases, Internal Medicine, Neurology, Oncology, Ophthalmology, Orthopaedic, Pain Management, Pediatrics, Psychiatric, Vascular, and Weight Loss), sourced from more than 40 global pharmaceutical partners and commercialized for global healthcare companies seeking to reach Middle East markets.
  • VIZZ (aceclidine ophthalmic solution) Aceclidine ophthalmic solution for the treatment of presbyopia, commercialized in the Middle East under an exclusive partnership with LENZ Therapeutics. Lunatus holds exclusive commercialization rights across nine Middle Eastern countries.
  • Regulatory Affairs Services Regulatory support delivered through an in-house regulatory team that works hand-in-hand with the company's legal counsel to navigate complex Middle East approval requirements for partnered pharmaceutical and healthcare products.
  • Sales Services Sales force deployment and execution for partnered pharmaceutical and healthcare products across the Arabian Gulf and Middle East region.
  • Marketing Services Comprehensive marketing strategy crafting and execution for partnered healthcare brands across the Middle East region.
  • Distribution Services Distribution strategy and execution that delivers partnered pharmaceutical and healthcare products across nine Middle Eastern countries (UAE, Saudi Arabia, Kuwait, Qatar, Bahrain, Oman, Jordan, Lebanon, and Iraq).
  • Supply Chain Management Services Reliability-focused supply chain management woven into every stage of the product lifecycle, ensuring product security for partnered pharmaceutical and healthcare brands across the Middle East.

Companies that use Lunatus

Customer profile

Named customers1 record

Segments1 record

Ideal customer profiles1 record

Lunatus technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Lunatus partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered core.

  • LENZ TherapeuticscoreChannel Partner/ Reseller/ Distributor · 5 January 2026Exclusive commercialization partnership for VIZZ (aceclidine ophthalmic solution) for treating presbyopia in the Middle East region, covering UAE, Saudi Arabia, Kuwait, Qatar, Bahrain, Oman, Jordan, Lebanon, and Iraq. LENZ receives upfront, regulatory and commercial milestone payments plus a significant share of revenue, while Lunatus retains exclusive commercialization rights. This is LENZ's fourth international commercialization partnership for VIZZ, which received FDA approval in July 2025 and launched in the US in September 2025.
  • 40+ Global Healthcare CompaniescoreChannel Partner/ Reseller/ DistributorPartnered with over 40 global companies offering 300 diverse product lines to meet the growing healthcare needs of the Middle East region across cardiovascular, dermatology, ENT, gastroenterology, gynecology, infectious diseases, internal medicine, neurology, oncology, ophthalmology, orthopaedic, pain management, pediatrics, psychiatric, vascular, and weight loss categories.

Scale indicators4 records

Recent moves4 records

Expansion highlights4 records

Lunatus competitors and assessment

Company assessment

Direct peers

  • Algorithm SAL: Lebanon-based pharmaceutical company with manufacturing and regional distribution across MENA, including in-licensed and proprietary branded generics. Comparable regional pharmaceutical distributor serving overlapping Middle Eastern markets.
  • Tabuk Pharmaceuticals: Saudi-based pharmaceutical company with manufacturing, in-licensing, and regional distribution across multiple therapeutic categories. Directly comparable to Lunatus's business model of partnering with global innovators for Middle East commercialization.
  • Neopharma: Abu Dhabi-headquartered pharmaceutical manufacturer with regional distribution across the GCC. Operates a similar in-licensing and distribution model serving MENA markets and overlapping with Lunatus's therapeutic categories.
  • Julphar (Gulf Pharmaceutical Industries): Ras Al Khaimah-based pharmaceutical manufacturer and distributor with broad MENA presence across multiple therapeutic categories. Direct comparable: UAE-headquartered pharma player offering branded generics and licensing partnerships across the same Gulf geographies Lunatus serves.
  • Pharmax Pharmaceuticals: UAE-based pharmaceutical company specializing in branded generics and in-licensed products with regional distribution across the Middle East. Closely comparable business model — in-licensing, marketing, and distribution via regional channel partners.
  • SPIMACO (Saudi Pharmaceutical Industries & Medical Appliances): Saudi-listed pharmaceutical manufacturer and distributor serving KSA and export markets with branded and licensed products. Comparable regional distribution footprint and licensing/partnership-driven model targeting the same Middle Eastern customer base as Lunatus.
  • Jamjoom Pharmaceuticals: Saudi-based pharmaceutical company with manufacturing, marketing, and distribution of branded generics and licensed products across MENA. Comparable in-licensing/distribution orientation and GCC market focus.

Broad incumbents

  • Cipla: India-headquartered global pharmaceutical major with active presence in the Middle East via distribution partnerships and direct operations. Comparable as both a potential partner to Lunatus and a broader incumbent operating in the same regional channel.
  • Hikma Pharmaceuticals: Jordan-headquartered multinational pharmaceutical company with deep MENA commercial infrastructure, branded and generics portfolio, and a licensing/distribution model overlapping Lunatus's go-to-market. Larger and more diversified, but operates in the same channel.

Regional players

  • Acino International: Switzerland-headquartered but with a strong Middle East/Turkey focus for specialty pharmaceuticals via partnerships and out-licensing. Comparable as a partner-to-Lunatus originator (or regional distributor) rather than a direct competitor in the Gulf.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

Lunatus social profiles

Digital presence

Lunatus financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Lunatus leadership team

Management profile

Number of profiles

Profiles1 record

Lunatus funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Lunatus M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Lunatus

What does Lunatus do?

Lunatus acts as a full-service healthcare commercialization partner for global pharmaceutical and healthcare companies seeking to enter Middle East markets. The company delivers integrated regulatory, sales, marketing, distribution, and supply chain solutions, and commercializes a portfolio of 300+ product lines across 16 therapeutic categories sourced from 40+ international partners. Its core revenue model combines exclusive distribution rights with milestone payments and revenue shares from partnered product launches in the Arabian Gulf region.

Is Lunatus a public or private company?

Lunatus is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Lunatus founded?

Lunatus was founded in 2003. It employs 101 to 250 people.

Where is Lunatus based?

Lunatus is headquartered in Dubai, United Arab Emirates, in the Middle East region.

How does Lunatus make money?

One revenue line is on record: distribution and Commercialization Rights.

Who are Lunatus's main competitors?

Direct peers on record are Algorithm SAL, Tabuk Pharmaceuticals, Neopharma, Julphar (Gulf Pharmaceutical Industries), Pharmax Pharmaceuticals, SPIMACO (Saudi Pharmaceutical Industries & Medical Appliances) and Jamjoom Pharmaceuticals. Broad incumbents are Cipla and Hikma Pharmaceuticals. Acino International is listed as a regional player.

Does Lunatus have an API?

No public API is recorded for Lunatus.

What industry is Lunatus in?

Lunatus's product category is Pharmaceutical Distribution and Commercialization Services. Its primary akta.pro industry code is HLAIAJAO, Compounding Ingredient & API Distributors (Pharma Supply), with a secondary code of MPAAAFAL, International / Market Entry & Expansion Marketing Strategy. Its NAICS code is 424210 and its SIC code is 5122.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals